Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S G Gourlay

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Lancet (London, England)|June 15, 1991
Tobacco smoking controlS G Gourlay
Journal of the American College of Cardiology|June 1, 1997
Cardiovascular toxicity of nicotine: implications for nicotine replacement therapyN L Benowitz, S G Gourlay
Clinical Pharmacology and Therapeutics|November 14, 1997
Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotineS G Gourlay, N L Benowitz
Drugs|August 1, 1995
Is clonidine an effective smoking cessation therapy?S G Gourlay, N L Benowitz
The Medical Journal of Australia|December 3, 1990
Antismoking productsS G Gourlay, J J McNeil
Drugs & Aging|July 1, 1996
The benefits of stopping smoking and the role of nicotine replacement therapy in older patientsS G Gourlay, N L Benowitz
Clinics in Dermatology|October 27, 1998
Clinical pharmacology of nicotineS Zevin, S G Gourlay, N L Benowitz
The Cochrane Database of Systematic Reviews|May 5, 2000
Clonidine for smoking cessationS G Gourlay, L F Stead, N L Benowitz
The Cochrane Database of Systematic Reviews|July 22, 2004
Clonidine for smoking cessationS G Gourlay, L F Stead, N L Benowitz
Drug Safety|July 7, 1999
Predictors and timing of adverse experiences during trandsdermal nicotine therapyS G Gourlay, A Forbes, T Marriner, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Lancet (London, England)|June 15, 1991
Tobacco smoking controlS G Gourlay
Journal of the American College of Cardiology|June 1, 1997
Cardiovascular toxicity of nicotine: implications for nicotine replacement therapyN L Benowitz, S G Gourlay
Clinical Pharmacology and Therapeutics|November 14, 1997
Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotineS G Gourlay, N L Benowitz
Drugs|August 1, 1995
Is clonidine an effective smoking cessation therapy?S G Gourlay, N L Benowitz
The Medical Journal of Australia|December 3, 1990
Antismoking productsS G Gourlay, J J McNeil
Drugs & Aging|July 1, 1996
The benefits of stopping smoking and the role of nicotine replacement therapy in older patientsS G Gourlay, N L Benowitz
Clinics in Dermatology|October 27, 1998
Clinical pharmacology of nicotineS Zevin, S G Gourlay, N L Benowitz
The Cochrane Database of Systematic Reviews|May 5, 2000
Clonidine for smoking cessationS G Gourlay, L F Stead, N L Benowitz
The Cochrane Database of Systematic Reviews|July 22, 2004
Clonidine for smoking cessationS G Gourlay, L F Stead, N L Benowitz
Drug Safety|July 7, 1999
Predictors and timing of adverse experiences during trandsdermal nicotine therapyS G Gourlay, A Forbes, T Marriner, et al.
Pageof 2